huntington's disease research paper

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts
• 30 May 2018

Huntington’s disease: 4 big questions

• Anna Nowogrodzki 0

Anna Nowogrodzki is a freelance science writer based near Boston, Massachusetts.

You can also search for this author in PubMed   Google Scholar

1. How does the mutant protein huntingtin cause Huntington’s disease?

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 51 print issues and online access

185,98 € per year

only 3,65 € per issue

Rent or buy this article

Prices vary by article type

Prices may be subject to local taxes which are calculated during checkout

Nature 557 , S48 (2018)

doi: https://doi.org/10.1038/d41586-018-05180-3

This article is part of Nature Outlook: Huntington’s disease , an editorially independent supplement produced with the financial support of third parties. About this content .

Related Articles

Partner content: Our inspiration: people impacted by Huntington’s disease

• Neurodegeneration
• Neuroscience

This fMRI technique promised to transform brain research — why can no one replicate it?

News 11 APR 24

Innate immunity in neurons makes memories persist

News & Views 27 MAR 24

Memories are made by breaking DNA — and fixing it

News 27 MAR 24

The rise of eco-anxiety: scientists wake up to the mental-health toll of climate change

News Feature 10 APR 24

Metabolic rewiring promotes anti-inflammatory effects of glucocorticoids

Article 10 APR 24

Use fines from EU social-media act to fund research on adolescent mental health

Correspondence 09 APR 24

Diabetes drug slows development of Parkinson’s disease

News 03 APR 24

Ancestral allele of DNA polymerase gamma modifies antiviral tolerance

Article 03 APR 24

Non-neuronal brain cells modulate behaviour

News & Views 28 FEB 24

Junior Group Leader Position at IMBA - Institute of Molecular Biotechnology

The Institute of Molecular Biotechnology (IMBA) is one of Europe’s leading institutes for basic research in the life sciences. IMBA is located on t...

Austria (AT)

IMBA - Institute of Molecular Biotechnology

Open Rank Faculty, Center for Public Health Genomics

Center for Public Health Genomics & UVA Comprehensive Cancer Center seek 2 tenure-track faculty members in Cancer Precision Medicine/Precision Health.

Charlottesville, Virginia

Center for Public Health Genomics at the University of Virginia

Husbandry Technician I

Memphis, Tennessee

St. Jude Children's Research Hospital (St. Jude)

Lead Researcher – Department of Bone Marrow Transplantation & Cellular Therapy

Researcher in the center for in vivo imaging and therapy.

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

The Neuropsychology of Huntington's Disease

Affiliations.

• 1 Greater Manchester Neuroscience Centre, Salford Royal NHS Trust, Salford, UK.
• 2 Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
• PMID: 28961886
• DOI: 10.1093/arclin/acx086

Huntington's disease is an inherited, degenerative brain disease, characterized by involuntary movements, cognitive disorder and neuropsychiatric change. Men and women are affected equally. Symptoms emerge at around 40 years, although there is wide variation. A rare juvenile form has onset in childhood or adolescence. The evolution of disease is insidious and structural and functional brain changes may be present more than a decade before symptoms and signs become manifest. The earliest site of pathology is the striatum and neuroimaging measures of striatal change correlate with neurological and cognitive markers of disease. Chorea and other aspects of the movement disorder are the most visible aspect of the disease. However, non-motor features have greatest affect on functional independence and quality of life, so require recognition and management. The evidence-base for non-pharmacological treatments in Huntington's disease is currently limited, but recent intervention studies are encouraging.

Keywords: Basal ganglia; Congenital/genetic Disorders; Executive functions; Huntington's disease; Movement disorders; Subcortex.

© The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected].

Publication types

• Huntington Disease / physiopathology*
• Huntington Disease / psychology*
• Neuropsychology

• hd research
• learn about hd research

Learn About HD Research

Stay up to date on HD research by following HDSA research communications.

Research Blog

This Week in HD Research is a weekly blog from Dr. Leora Fox , covering HDSA research activities, recently published work about HD, historical moments in HD research, and more. >

HDSA Research Webinars

HDSA invites clinicians and scientists to present directly to families about their recent work, online and at our National Convention. >

HD research news, proudly supported by HDSA, written by scientists in plain language. >

HD Therapies in Pipelines

A map of HD research studies and their progress through the clinical pipeline. >

Annual Research Reports

Comprehensive end-of-year reports about HDSA research activities and advancements in HD science. >

HD-COPE helps give patients a direct voice in clinical research by facilitating communication between the HD community and pharmaceutical companies working on drugs for HD. >

HDSA Scientific Advisory Board

HDSA’s Scientific Advisory Board, made up of world-renowned HD doctors and researchers, carefully reviews funding applications and discusses the direction of HDSA research funding. >

Spotlight on HD Researchers

Meet HDSA-funded researchers from around the world working on meaningful science to combat Huntington’s disease. >

Share a link

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• Dialogues Clin Neurosci
• v.18(1); 2016 Mar

Language: English | Spanish | French

Huntington disease: a single-gene degenerative disorder of the striatum

Enfermedad de huntington: un trastorno degenerativo monogénico del estriado, la maladie de huntington : une affection dégénérative monogénique du striatum, peggy c. nopoulos.

Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA

Huntington disease (HD) is an autosomal dominant, neurodegenerative disorder with a primary etiology of striatal pathology. The Huntingtin gene (HTT) has a unique feature of a DNA trinucleotide (triplet) repeat, with repeat length ranging from 10 to 35 in the normal population. Repeat lengths between 36 and 39 cause HD at reduced penetrance (some will get the disease, others won't) and when expanded to 40 or more repeats (mHTT), causes HD at full penetrance (every person with this length or beyond will definitely develop the disease). The symptoms of HD may be motor, cognitive, and psychiatric, and are consistent with the pathophysiology of frontostriatal circuitry malfunction. Expressed ubiquitously and throughout the entire life cycle (development through adulthood), mHTT causes initial dysfunction and eventual death of a specific cell population within the striatum. Although all areas of the brain are eventually affected, the primary pathology of the disease is regionally specific. As a single-gene disorder, HD has the distinction of having the potential of treatment that is aimed directly at the known pathogenic mechanism by gene silencing, providing hope for neuroprotection and ultimately, prevention.

La Enfermedad de Huntington (EH) es un trastorno neurodegenerativo autosómico dominante con una etiología primaria de la patología estriatal. El gen de la proteína huntingtina (HTT) tiene una característica distintiva cual es la repetición del trinucleótido de DNA (triplete), con una longitud de repetición que va de 10 a 35 veces en la población normal. Las longitudes de repetición entre 36 y 39 veces provocan una EH de pene-tración reducida (algunos adquirirán la enfermedad y otros no) y cuando se expanden a 40 o más repeticiones (mHTT), se provoca la EH de penetración completa (cada persona con esta longitud o más desarrollará definitivamente la enfermedad). Los síntomas de la EH pueden ser motores, cognitivos y psiquiátricos y son consistentes con la fisiopatología de un mal funcionamiento del circuito fronto-estriatal. El mHTT provoca una disfunción inicial y la eventual muerte de una población celular específica dentro del estriado, al expresarse de manera ubicua y durante toda la vida (con un desarrollo en la adultez). Aunque todas las áreas del cerebro están eventualmente afectadas, la patología primaria de la enfermedad ocurre en una región específica. Como un trastorno monogénico, la EH se distingue por tener una terapéutica potencial dirigida directamente al mecanismo patogénico conocido como el silenciamiento génico, dando esperanzas de neuroprotección y finalmente de prevención.

La maladie de Huntington (MH) est une affection neu-rodégénérative autosomique dominante dont l'étiologie primaire est une maladie du striatum. Le gène de la protéine Huntingtine (HTT) se présente sous la forme particulière d'une répétition d'un trinucléotide de l'ADN (triplet), la longueur de la répétition variant de 10 à 35 fois dans la population normale. Des longueurs répétées entre 36 et 39 fois provoquent une MH à pénétrance réduite (certains auront la maladie, d'autres non) et des répétitions de 40 fois et plus (HTTm) entraînent une MH à pénétrance complète (chaque personne porteuse de cette longueur et au-delà développera la maladie de façon certaine). Les symptômes de la MH peuvent être moteurs, cognitifs et psychiatriques et concordent avec la physiopathologie d'une dysfonction du circuit striato-frontal. Exprimé de façon ubiquitaire et tout au long d'une vie entière (il se développe pendant toute la vie adulte), le gène HTTm est responsable de la dysfonction initiale et de la mort finale d'une population cellulaire spécifique dans le striatum. Toutes les zones cérébrales sont finalement touchées mais la pathologie primaire de la maladie est spécifique localement. En tant qu'affection monogénique, la MH a la particularité de pouvoir bénéficier d'un traitement dirigé directement contre le mécanisme pathogène connu par silençage génique, ce qui est porteur d'espoir pour la neuroprotection et enfin pour la prévention.

Introduction

Huntington disease (HD) is an autosomal dominant, neurodegenerative disorder with a primary etiology of corticostriatal pathology. HD is caused by a DNA trinucleotide (triplet) repeat expansion of equal to or greater than 40 CAG repeats within the gene Huntingtin (HTT, OMIM 613004). Repeat numbers vary from 6 to 35 in the general population. When there are less than 27 repeats, there is no manifestation of HD, and the gene is stable upon transmission. Repeat lengths in the range of 27 to 35 also are not associated with development of HD; however, there is a possibility of expansion upon transmission, giving rise to the phenomenon of genetic anticipation. Expansion upon transmission is more likely at longer repeat lengths within this range, and is also more likely to happen during male transmission. 1 CAG repeats in the range of 36 to 39 are of incomplete penetrance with variable disease manifestation.

Phenomenology

HD is a rare disease with a prevalence of approximately 10 to 12 individuals per 100 000 of European ancestry. 2 The number of repeats in HTT is inversely associated with disease onset such that the greater the number, the earlier the onset. 3 Onset of disease is defined as manifestation of significant motor or neurologic symptoms and occurs on average around the age of 40. Although the number of repeats in HTT accounts for roughly 50% to 70% of the variance in age of onset, 4 there remain other influential factors yet to be defined; these are likely to be environmental elements or modifying gene factors. Although repeat length does not account for all of the variance in age of onset, the strong relationship allows for some generalizations. ( Figure 1 ). displays the general relationship between age of onset and CAG repeat number.

Those with later onset are more likely to have fewer repeats, sometimes in the intermediate range. Classic adult onset between the ages of 30 and 50 are associated with repeat lengths between 40 and 49. Repeat lengths larger than 50 are typically associated with onset between 20 and 30 years of age. When disease onset occurs prior to the age of 21, it is referred to as juvenile HD (JHD), which constitutes about 5% of all HD cases. 5 Within JHD, repeat lengths greater than 60 are associated with age of onset between 10 and 20, and the very highest repeat numbers — over 80 — can manifest in childhood onset, where the diagnosis is made before the age of 10. The earliest reported diagnosis was in an 18-month-old with a repeat length over 200 . 6

The course of disease in HD is relatively long compared with other neurodegenerative disorders, lasting on average 15 years from diagnosis to death. Although the CAG repeat number is highly correlated with age of onset, it does not appear to have much impact on length of disease, suggesting that once the disease process begins, other factors determine course of disease rather than the length of the mutation. Stages of HD can be categorized based on the patient's functional capacity, which is expressed as a standardized scale. 7 The Shoulson-Fahn staging system ranges from stage 1 through stage 5 with the earliest stage having full functional capacity (early in the disease) and stage 5, severely limited functional capacity. Patients in stage 5 typically need total care and are most often in a nursing home.

Sine the discovery of the gene in 1993, it is possible to test persons who are at risk for HD (due to autosomal dominance, each child of a parent with HD has a 50% chance of inheriting the mutation). In terms of clinical aspects, at the age of 18 has been persons at risk can undergo presymptomatic testing to find out if they do indeed carry the mutant gene. This is a choice that relatively few people at risk (roughly 5% to 10%) choose to make, and it requires a multi visit protocol with genetic counselors, neurologists, and often a psychiatrist or psychologist.

Clinical symptoms

The clinical symptoms of HD are classically defined as occurring in three domains: motor, cognitive, and psychiatric. The motor symptoms are progressive and—early in the disease—are mostly hyperkinetic with involuntary movements of chorea. These movements generally begin distally and are of small degree, then become more axial and are of greater amplitude. Movements are often incorporated into natural voluntary movements and, thus, early on may appear as simple restlessness. Although the early stages of motor symptoms are hyperkinetic, in later stages of the disease, motor symptoms tend to be hypokinetic with bradykinesia and dystonia. 8 Other classic symptoms are motor impersistence and abnormal eye movements. Late in the disease, dysphagia becomes a symptom with high morbid impact, as aspiration is a common occurrence, and pneumonia is a common cause of death.

Cognitive dysfunction occurs in the vast majority of patients. In early stages, this can be somewhat limited to executive function, with difficulties in decision making, organization, planning, and multitasking. Eventually, these symptoms progress, and a more global picture of cognitive deficits emerges with an ultimate diagnosis of dementia. In general, the dementia of HD is considered to be “subcortical,” highlighting the involvement of the corticostriatal pathways. Key differences between HD dementia and a classic cortical dementia is that, in memory tasks, patients with HD can recall items better if cued, suggesting that it involves an inefficient search of memory rather than a deficient memory per se. In general, memory loss occurs later in HD, and problems that are typical of cortical dementias, such as aphasia and apraxia, are not as common in HD. Importantly, the cognitive deficits in HD may precede the motor symptoms by many years. It is not uncommon in a clinical setting to have a formal clinical diagnosis of HD made for the first time based on motor abnormality though the cognitive deficits have already reached the level of dementia.

Psychiatric symptoms associated with HD can span a variety of domains; however, the most common symptoms are consistent with frontal lobe dysfunction, in line with the known pathophysiology of the disease. 9 Initially, these symptoms are in the domain of frontal disinhibition, with symptoms of poor attention, irritability, impulsivity, and poor mood regulation. Early in the disease course, family members often conceptualize such symptoms as a personality change. The irritability associated with HD can be severe, and results in outbursts of anger and aggression, with prevalence recently reported as being as high as between 22% and 66% of patients. 10 Later in the disease, the symptoms often take on more of a frontal abulic constellation of symptoms, with prominent apathy or loss of initiative, creativity, and curiosity. This is accompanied by pervasive emotional blandness. Family members often interpret these symptoms as depression, and objectively, the patient certainly appears more withdrawn, uninterested, and noninteractive. However, subjectively, patients will deny any feelings of sadness or hopelessness and typically describe their mood as fine or good. These frontal lobe symptoms (disinhibition and abulia) of HD are a likely manifestation of the frontostriatal pathology of degeneration. Apathy is, in general, the most common feature of the disease, occurring at the highest prevalence and is progressive, 11 tracking along with other progressive features such as motor symptoms and cognitive decline.

Depression is a feature that is commonly reported to be associated with HD. 12 However, what is not clear is whether depressive symptoms are a manifestation of the disease process with direct connections to the neural underpinnings of pathology. Importantly, the course of depressive symptoms is opposite what one would expect if these symptoms were core features that were directly linked to the pathophysiology of the degenerative process. That is, depression is most common at early points in the illness—the first period is right around the time of diagnosis, and the second is during stage 2 when some impairment begins to hamper function. 13 However, from this point on, depressive symptoms appear to decline in prevalence. Parallel with this time course is risk of suicide, which is highest near the time of diagnosis and which then drops off and diminishes after that. 14 Given the course of a degenerative disease, any associated symptom that is present early in the course of disease but lessens with time suggests that it is not the underlying pathology leading to depressive symptoms. It may well be that the increase in depressive symptoms occurring early in the course of disease may be due to an appropriate psychological reaction to the stressors of dealing with either the knowledge or the emergence of a fatal brain disease. Despite the etiology of depressive symptoms in HD, the treatment of these symptoms and the need for careful screening of suicide risk remains a vital part of the care of this patient population.

A prominent feature of HD is lack of awareness or lack of insight into the nature or severity of symptoms that the patient is experiencing. This can include lack of awareness of any feature of the disease, including all three domains of motor, cognitive, or behavioral symptoms. 16 , 15 This feature makes it important to consider family members as helpful (sometime crucial) sources of information who provide objective appraisals of the patient's symptoms and level of function, and they should be involved in the patient's health care assessments and decision making.

The gene HTT is but one in a class of genes in which a CAG repeat (triplet coding for glutamine, represented as Q) is present, which when expanded causes brain disease. These can be classified as the polyQ (meaning repeating glutamine) diseases and include spinocerebellar ataxia (of which there are several types), dentatorubropallidoluysian atrophy (DRPLA) and spinal and bulbar muscular atrophy (SBMA). All polyQ diseases share the features of being autosomal dominant and causing disease when the number of CAG repeats crosses a certain threshold. Beyond polyQ diseases, there are several other diseases that are caused by triplet repeat, and these include fragile X syndrome (CGG repeat), Friedreich ataxia (GAA repeat), and myotonic dystrophy (CTG repeat).

Although a lot of work has been done on the study of the expanded or mutant form of HTT (mHTT), there has been relatively little work on understanding the normal gene and its function. 17 Some of this is due to the large size of the huntingtin protein (making isolation difficult), the fact that it is located everywhere in the body (ubiquitous expression), and that, within the cell, it interacts with more than 200 partners/proteins. 18 What is known is that like other homopeptide-repeatcontaining proteins, huntingtin functions by creating m ul ti protein complex form at ions. The actual function is not clear and may vary, but reports support functions in transcriptional regulation, nucleocytoplasmic shuttling, synaptic function, and antiapoptic activity. 19

It is also known that HTT is a highly conserved gene. However, the CAG repeats in the gene are not conserved. Work by Tatari et al 20 demonstrated that phylogenetic comparison of HTT homologs reveal the appearance of repeats first in deuteros tomes, and the repeats then increase — the more evolved the species, the greater the number of repeats, with humans having the highest number. For this and a number of reasons, it has been postulated thaXHTT, and possibly other genes like it, may have an important role in the evolution of the brain from primate to human. 21

In terms of mHTT and the disease process, the conundrum is that, despite ubiquitous expression throughout the entire body and from conception through adulthood, the primary site of pathology is specific to the striatum. Even more specific is the type of neuron that is most vulnerable. Striatal GABAergic spiny projection neurons (SPNs) come in two types, as follows: indirect pathway SPNs (iSPNs), which suppress inappropriate movements, and direct pathway SPNs (dSPNs), which promote appropriate movements. It is the iSPNs that are affected first and are consistent with the manifestation of chorea as the presenting motor abnormality. Later in the disease, dSPNs are affected, leading to the hypokinetic motor symptoms of later-stage disease.

Most recent evidence points to the pathophysiology of mHTT being the impairment of cortical pyramidal neurons to provide the striatum with needed brain derived neurotrophic factor (BDNF). 22 , 23 This has been said to lead to the ”withering“ of the striatal cells. Although eventually all regions and tissues of the brain are affected, the disease process is clearly selective and specific to the striatum.

Another major theme in the research on etiology of HD is the disturbance of cell metabolism. Biochemical studies have shown disrupted metabolic processes of post-mortem HD brains 24 and lymphoblast cell lines of HD patients. 25 Impaired energetics in HD were not limited to neuronal tissues and were also found in HD adult skeletal muscles, 26 - 28 implying an integral role for huntingtin in mitochondrial energy metabolism. This disturbance in metabolism has been linked clinically to the symptoms of lower weight and body mass index (BMI) in patients with HD. This has been shown to be independent of the amount of chorea that is present, and in later stages of the disease, it can lead to cachexia. More importantly, low BMI is present in preHD subjects and points to an energy imbalance that may be primary to the disease process. 29 , 30

The role of abnormal development

In general, HD is classically conceptualized as a neurodegenerative disease of the striatum. However, multiple lines of evidence support the theory that abnormal brain development may play an important role in the etiology of HD, as well as other degenerative brain disorders. Abnormal development and degeneration are not mutually exclusive. There is no doubt that HD is a neurodegenerative disorder. However, persuasive work in molecular biology has supported the theory of neurodevelopmental mechanisms of degeneration. This theory suggests that neurodegenerative diseases such as Alzheimer disease and HD may represent a novel class of developmental disorders in which subsets of neural populations are vulnerable because of abnormal development, and exist in a mutant steady state before succumbing to environmental stressors or toxins that normally would not promote cell death. 31

Huntingtin and development

Normal HTT is necessary for brain development; embryos of HTT knock-out mice have major abnormalities in central nervous system development and die shortly after birth. 32 It is also known that HTT is expressed in the brain throughout development 33 , 34 and plays a vital role in neuronal survival and stability. 35 Therefore, given HTTs key role in development, a partial loss of function may manifest in abnormal neural development. Although the classic theory of HD etiology is that mutant HTT (mHTT) results in a gain-of-function toxicity that results in neural damage, there is also compelling evidence that in addition to this mechanism, loss of function of normal HTT may also be an important mechanism in the disease. 17 , 36

More recent work by Nguyen et al 37 has shown that HTT is essential for the program of neural induction, progressive specification of neural progenitor cell types, and the subsequent elaboration of neural lineage species. Moreover, mHTT was shown to cause impairments in multiple stages of striatal development, supporting the notion that the selective vulnerability of striatal neurons may have a developmental etiology. 37

One of the benefits of the HTT gene discovery was the opportunity it afforded to study presymptomatic HD subjects, also known as preHD. This allows the measurement of brain structure and function in people who are years from the onset of disease. One large multisite study with more than 1300 at-risk adults enrolled has shown that preHD subjects exhibit abnormalities in brain structure, cognition, behavior, and motor function long before (up to 20 years) a clinical diagnosis is made. 9 , 38 - 46 Multiple other studies, both large and small, have also found abnormalities in preHD adults decades before onset. 47 - 51 Some have suggested that these changes are due to early degeneration. 52 - 54 However, an alternate explanation is that these subtle symptoms are manifestations of abnormal brain development and are present throughout life.

If it is true that HD has a vital portion of its pathophysiology based in abnormal development, a conceptual shift in our understanding of this disease (and other degenerative disorders) will be in order. The current etio logic dogma of HD is that the disease process lies within the toxic effects of mutant huntingtin (encoded by mHTT), which accumulates in the cell, is toxic, and causes degeneration. An alternative theory is that HTTs vital role in development is compromised in the mHTT form, leading to abnormal development, which is, in and of itself, part of the disease process. This mutant neuronal circuit is initially able to compensate and remain relatively functional, though with subtle abnormalities (mutant steady state). Later, maturation and aging processes (and toxic effects of mutant huntingtin) eventually tip the faulty circuit toward degeneration. A schematic of the model is shown in ( Figure 2 ).

Evidence of abnormal brain development in human research includes one large magnetic resonance imaging study showing that pre-HD males had smaller intracranial volumes (ICV) than healthy controls. 40 ICV is a proxy measure of maximum brain growth during development; therefore, lower ICV is indicative of poor general brain growth. Also, a unique study of children at risk for HD has shown that children who are preHD (average age 12) have lower BMI and smaller head circumference values than healthy controls, again supporting the notion that abnormal growth may be a vital part of the pathologic process in HD. 55

Juvenile Huntington disease

Longer expansions of HTT cause early onset of the disease. When this occurs prior to age 21, it is termed JHD. JHD is similar to adult-onset HD in many ways, with the same triad of motor, cognitive, and psychiatric symptoms. However, one distinct difference is the presentation and predominance of motor symptoms: In adult-onset HD, early motor symptoms are chorea/hyperkinetic and later on, hypokinetic. In JHD, the motor presentation is typically hypokinetic with bradykinesia/ stiffness/dystonia and may become hyperkinetic later in the disease. 56 One other accompanying feature that is somewhat unique to JHD is seizures. Most common in childhood-onset JHD (diagnosed before the age of 10), seizures can be severe and difficult to treat. 57 The cognitive changes in JHD are progressive but, in the context of children, may also affect their ability to learn and obtain skills before degeneration of those skills occurs. Of the symptoms of JHD, the psychiatric and behavioral symptoms are far more consistent and prominent. That is, most patients will have behavioral symptoms. In one large study, 70% of JHD subjects presented with behavioral symptoms; during the course of disease, 93% of males and 81% of females experienced psychiatric issues. 58 These symptoms are made up almost exclusively of externalizing behaviors of hyperactivity, impulsivity, poor mood regulation, irritability, and anger outbursts. Although there is a perception that JHD patients may have a more rapid disease course than those with adult onset, the literature has conflicting reports, leaving it a question that has yet to be fully explored. 56

Gene therapy

By far the most exciting and promising advances in research on HD have been made in the work toward treatment with gene therapy. A potential therapeutic for dominant genetic disorders, silencing of mutant genes provides the opportunity for treatment with major impact. In general, the promise of gene therapy could be twofold: (i) restoration of function by returning to health neuronal circuits that are not yet dead, but dysfunctional and (ii) neuroprotection with a lack of disease progression. In fact, the ultimate use of gene therapy would not be in treatment, but in prevention of disease — avoidance of symptoms entirely. The approaches of gene therapy are based on targeting the processes of DNA information being copied into messenger RNA or mRNA (a process called transcription) and on the synthesis of proteins using the information in mRNA (a process called translation). Gene-silencing techniques have three general approaches, as follows: repression of transcription using zinc finger proteins, repression of translation of mHTT by antisense oligonucleotides (ASOs), and blocking protein translation using RNA interference techniques. 59 The large neuroimaging studies done in preHD and early-stage patients have shown that quantitative measures of brain regions such as the striatum are excellent biomarkers of disease progression and will be useful in the context of the upcoming gene therapy studies. 42 , 60 , 61

HD, a single-gene degenerative disorder of the striatum, has seen more than two decades of intense research, spurred by the identification of the gene in 1993. This research has led to a better understanding of the pathoetiology of the disease; however, there is much still to be studied, especially in the context of understanding the role of abnormal development. In addition, very little is known about the normal function of HTT, which is vital to brain development. Despite these areas of uncertainty, much progress has been made, particularly regarding the promise, and now reality, of new methods of treatment and potential prevention in the context of gene therapy approaches.